Overview Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. Status: Recruiting Trial end date: 2025-06-01 Target enrollment: Participant gender: Summary The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety， tolerability and efficacy of FS-1502. Phase: Phase 1 Details Lead Sponsor: Shanghai Fosun Pharmaceutical Development Co, Ltd.